高盛-中国CRO及CDMO行业:2026年三季报总结:强劲订单巩固2027年业绩展望尽管近期市场波动_第1页
高盛-中国CRO及CDMO行业:2026年三季报总结:强劲订单巩固2027年业绩展望尽管近期市场波动_第2页
高盛-中国CRO及CDMO行业:2026年三季报总结:强劲订单巩固2027年业绩展望尽管近期市场波动_第3页
高盛-中国CRO及CDMO行业:2026年三季报总结:强劲订单巩固2027年业绩展望尽管近期市场波动_第4页
高盛-中国CRO及CDMO行业:2026年三季报总结:强劲订单巩固2027年业绩展望尽管近期市场波动_第5页
已阅读5页,还剩23页未读, 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

htEtqpi:t/wse.vaaruhelist

12November2026|12:46AMHKT

CHINACRO&CDMO

3Q26Wrap-up:Robustordersreinforce2027visibilitydespiterecentmarketvolatility

Bottomline:StrongYTDperformanceandpositioninghaveraisedthebar,with

WuXiAppTecbecomingatop-10holdingamongChinaonshoremutualfunds

alongsidemajortechnologynamesasof3Q(seethenewshere),butfundamentals

remainedonanupwardtrajectory.Robust3Qordermomentumcoupledwith

acceleratedcapacityexpansionprovideshighervisibilityformanufacturingbusinessinto2027,whileimprovingbiotechfunding,M&A/BDactivityandemergingAI-baseddrugdiscoveryactivitiessupportanupcycleforwet-labdemand.Geopolitics

newsflow(e.g.1260H/BIOSECUREOBMBCClist)couldstilldriveheadlinevolatility,butnear-termimplementationriskhasreduced(e.g.WuXiAppTec’sremovalfromthe1260Hlist),andlimiteddisruptiontoorderintakein2025/2026hasproventheresilienceofthebusinessamiduncertaintiestothemarket.

Strong3Qdeliveryandrobustordersreinforce2027visibility,withtherecoverybroadening:3Q26earningswerebroadlysolidacrossChinaCRO/CDMOsdespite

continuedFXheadwinds,whilenew-ordermomentumremainedstrongdespitea

higher2H25comparisonbase,withWuXiAppTecacceleratingtoc.60%yoyin9M26,Pharmaronatc.30%,Tigermedapproaching30%andAsymchemmaintainingc.30%growthin3Q.Guidanceupdateswerelargelyconsistentwithourexpectations

followingsignificantupgradesearlierthisyear,withWuXiAppTecthenotableupsiderevision,raisingFY26continuing-operationsrevenuegrowthguidanceto40%-42%from35%-39%.Capexplansalsoremainontrackfollowingincreasesearlierthis

year,withcompaniescontinuingtoinvestagainststrongerdemandandpipeline

visibility.Importantly,therecoveryisbroadeningbeyondlate-stagemanufacturing,withimprovingearly-stageactivity,LabServicesandpricing,whileAIDDisemergingasanincreasinglytangibleincrementaldemanddriverthroughgrowingwet-labanddata-generationdemandacrossWuXiAppTec,PharmaronandGenScript.

Recentshare-priceweaknesscreatesabettersetupasfundamentalsstrengthenandgeopoliticalimplementationriskeases:Despitesolidearningsandorders,

sectorshareshavecorrectedfollowingthestrongYTDre-rating,amidbroader

marketde-risking,profit-takingandrecurringgeopoliticalheadlines.Weseelimitedevidenceofdeteriorationinunderlyingdemand,suggestingpositioningandfund

flowshavebecomemoreimportantnear-termshare-pricedrivers.Meanwhile,WuXiAppTec’sremovalfromthePentagon’sSection1260Hlistreducestheriskof

inclusionontheinitialBCClistthroughthe1260Hpathway(notingthatinclusionon

ZiyiChen

+852-2978-0526|ziyi.chen@GoldmanSachs(Asia)L.L.C.

ChrisPan,CFA

+852-2978-7993|chris.pan@GoldmanSachs(Asia)L.L.C.

LinhaiZhao,Ph.D.

+852-3966-4059|linhai.zhao@GoldmanSachs(Asia)L.L.C.

EddieSong

+852-2978-6426|eddie.song@GoldmanSachs(Asia)L.L.C.

GoldmanSachsdoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethatthefirmmayhaveaconflictofinterestthatcouldaffecttheobjectivityofthisreport.

Investorsshouldconsiderthisreportasonlyasinglefactorinmakingtheirinvestmentdecision.ForRegAC

certificationandotherimportantdisclosures,seetheDisclosureAppendix,orgoto

/research/hedge.html.Analystsemployedbynon-USaffiliatesarenotregistered/qualifiedasresearch

analystswithFINRAintheU.S.

GoldmanSachs

tinpasC:/R/OwwC.DMO

theDepartmentofDefense’s1260Hlistisadirectpathwaytobeingdesignateda

companyofconcern),whileanalternativedesignationpathwayremains.Investor

attentionnowturnstotheDecember18initialBCC-listdeadlineandCOINS,where

biotechnology-rulecommentsaredueDecember7andfinalregulationsareexpected

bymid-March2027(seethenewshere).Webelievegeopoliticaldevelopmentscould

stillgenerateheadlinevolatility,butBIOSECUREimplementationriskhasmoderatedintoyear-end(wenoteremovalleavesopentheriskoffuturerelisting),whileCOINSwarrantsclosermonitoringgivenuncertaintyarounditsfinalscope,particularlyforNewCoand

co-developmentstructures.

Theinvestmentdebateisshiftingfromrecoverytoward2027executionand

conversion:Withdemandrecoveryandorderstrengthincreasinglyestablished,we

expectinvestorattentiontoshifttowardhoweffectivelybacklogconvertsintorevenueandnewcapacitytranslatesintoutilizationandearningsgrowth.Commercial-stage

conversionshouldbecomeanincreasinglyimportantdifferentiator,alongsideexecutioninfaster-growingmodalitiesincludingpeptides,ADCsand.We

thereforefavorcompanieswithstrongerordervisibility,greaterexposuretothesemodalitiesandclearerpathwaysfromlate-stageprojectsintocommercial

manufacturing.

Stockpicking:webelieveWuXiAppTec,PharmaronandGenScriptofferthree

differentiatedwaystopositionforthenextphaseofsectorgrowth:WuXiAppTec

(A/H)offersthestrongestcombinationofordermomentum,earningsvisibilityand

GLP-1/TIDESexposure;Pharmaron(H)providesleveragetoabroadeningrecovery

acrossbothLabServicesandCDMO;andGenScriptoffersdifferentiatedexposuretothestructuralAIDDopportunity.Followingtherecentsectorcorrection,webelieve

continuedfundamentaldeliveryandimproving2027visibilityshouldincreasingly

refocusinvestorattentiononunderlyingearningsandordertrends.Elsewhere,

Asymchem’s4Q26deliveryandWuXiXDC’sprogresstowardestablishingacommercialmanufacturingtrackrecordremainimportantproofpointsforbuildinginvestor

conviction.

12November20262

12November20263

Readacrossfromregionalpeersandglobalmacro

ImplicationsfromUSmidtermonpharma/biotech:PerAsad’snotehere,onpolicy

themes,theDemocraticsweepintheUSmidtermelectionhasexacerbatedinvestor

conversationsaroundtheinversedynamicbetweentheAI-exposedTechstocks(inthecontextofpotentiallystricterdatacenterregulation)andbiopharma,shoulda

broadeningouttradeinthemarketgainmoresteam.Whilewetakenoviewofany

policyoutcome,thepotentialforlegislativegridlockcoulddiminishthelikelihoodofanymaterialchangesinthenear-termtodrugpricing,consistentwiththeviewsofthe

panelistswehostedatourrecenttriptoWashington,D.C.Perourpoliticaleconomists,thelegislativeprioritiesfortheDemocratsrelevanttohealthcareareexpectedtocenteronexpandingcoverage(i.e.,ACA,Medicaid)andtryingtousefiscaldeadlinestoreverseOBBBdirectedcuts(includingtohospitals).Withthemidtermsnowbehindus,wecouldalsostarttoseetheM&Athemepickupwherewenotemultiplepotentialbiopharmaacquirershavesignaledappetiterecently(BMYsaidtheyareactivelyevaluatingmultipleopportunities,ABBVreferencedobesityandMRKcalledoutimmunologyofanareaofinterest).

Lonzaannouncedadditional5USCDMOsites:OnNov3rd,Lonzaannouncedthatit

hasagreedtoacquire5CDMOsitesfromMerckKGaAintheUSforalowtomidtriple

digitCHFmnamount(GSeCHF300-400m).TheacquisitionwouldmeanLonzawould

have9sitesintheUS(from4currently)tofillsomegapsacrosstheLonzaportfolio,

including(1.)US-basedbioconjugationandlinkercapabilitiesand(2.)inCell&Gene

therapies,whereLonza’scurrentnetworkisfocusedoncelltherapies,whiletheMerck

portfolioallowsexpansionintoviralvectors.Currentsalessplitsincludebioconjugates

(60-70%ofnetworksalescurrently)andtheviralvectorportionofthebusiness

(15-20%ofsales).Lonzanotedthatthedealwillbegrowthaccretive,withsalesinthe

firstfullyearpost-close(2028)ofaroundCHF250m,andthatthisdealwillbe

significantlyaheadofthe1:1investmenttopeaksalesratio,whichalsosuggeststhatthedealwilllikelybeROICaccretivebythetimeitreachespeaksales.(SeeJamesQuigley’snotehere.)WewillcloselymonitorthepotentialimpactforWuXiXDContheir

commercialtrackrecordbuilding.

SamsungBio:1)Laborstrikeimpactappearsmanageabledespiteanother

three-weekaction:Anew3-weeklaborunionstrikestartedonNov.6,withmedia

reportsindicating(seethenewshere)thatc.400workersareparticipating,orc.10%ofunionmembers,acrossqualitycontrol,qualityassurance,logisticsandproduction.TheOct.16courtrulingexpandedthemanufacturingprocessesrequiredtomaintainnormaloperationsduringindustrialactionfromthreedownstreamprocessestonineprocessesspanningupstreamcultivationthroughdownstreampurification,whichshouldreduce

near-termproduction-continuityrisk,althoughunderlyinglabornegotiationsremainongoing.2)Newordersarestartingtocomethrough,withfurtherconversion

expectedinto2027:Followingrelativelyslowerordersigningearlierthisyear,

managementindicatedthatnewcontractshavestartedtocomethroughinrecentweeks,whilecustomerinquiriescontinuetoimprove.Givencontractnegotiationstypicallytakemorethan12months,managementexpectsadditionalcontract

announcementsfrom4Q26through2027,althoughtimingcouldremainuneven.

GoldmanSachsChinaCRO&CDMO

Robustordersreinforce2027visibility

Exhibit1:Newordermomentumcontinuedin3Q

CDMOneworderandbackloggrowthsummary

Note:1)*forcontinuingoperations;2)neworderbasedonbacklogwithin3yearsforWuxiBiologics;3)cal.denotesneworderbasedoncalculation,restpercompanyCCY=constantcurrency,ex-FXimpact

Newordergrowth,yly

2023

2024

1Q252Q253Q254Q25

2025

1Q261H263Q26

WuXiAppTec

-1%(cal.)

30%“

25%°12%*18%°n.a

n.a.

ccy25%*(ccy40%5%)9M2660%+*

WuXiBiologicsWuXiXDC

15%(cal.)

n.a.

13%-15%°

n.a.n.a.n.a.n.a.

n.a.

n.a.n.a.n.a.

75%(cal.)

n.a.1H2548%n.a.2H2529(c%al.)

41%

n.a.47%(cal.)n.a.

Asymchem

n.a.

20%

Maintainthe9M25

momentumn.a.doubledigitn.a.

n.a.

n.a.55%(Aug26)c.30%

Tigermed

-19%

7%

AugYTD9M25

20%midteensmidteensn.a

21%

Highdoubledigit

30%+yly

9M2625-30%

Pharmaron

Labservice

CMC

Clinicaldevelopment

n.a.

n.a.

n.a.

>20%

15%

35%

10%

10%

10%

n.a.

n.a.

n.a

1H2510%

1H2510%

1H2520%

9M2513%

9M2512%

9M2520%

14%

12%

13%

30%

20%

50%

30%

20%

50%

30%

9M2630%

9M2625%

9M2640%

9M2625%

Note:1)*forcontinuingoperations;2)calculatedbasedondisclosedbacklogforWuXiAppTec,WuXiBio(backlogwithin3years),andWuXiXDC;

3)percompanyforAsymchem;4)WuxiXDC1H26growthonservicebacklog

Backloggrowth,yy

2023

202

1Q252Q253Q254Q25

2025

1Q261H263Q26

WuXiAppTec

7%

47%”

47%1H2537%*9M2541%°n.a

29%“(ccy34%)

24%

24%25%*36%*

(ccy29%)°(ccy30%)(ccy40%+)

n.a.24%°n.a.

WuXiBiologicsWuxiXDC

6%

82%

11%

n.a.

n.a.

1H2529%*1H2558%

n.a.

n.a.

n.an.a.

71%

50%

n.a.50%n.a.

Asymchem

Chemicalmacromolecule

BiologicalmacromoleculeDrugproducts

n.a.

n.a.

n.a.

n.a.

>20%

n.a.

n.a.

n.a.

n.a.

n.a.

n.a.

n.a.

n.a.

1H2590%1H2560%

1H2535%

n.a.

n.a.

n.a.

n.a.

n.a.n.a

n.a

n.a

32%

128%

56%

49%

n.a.

n.a.

n.a.

n.a.

54%(Aug

163%(Aug

89%(Aug

31%(Aug

26)

26)

26)

26)

n.a.

n.a.

n.a.n.a.

Source:Companydata,GoldmanSachsGlobalInvestmentResearch

Exhibit2:Strongbacklogonhandtofurthersupportthe2027toplinegrowth

FY20FY21

FY221H23

FY231H24

FY241H253Q25

FY251H263026

WuXiAppTec

Backlog,Rmbbn

15.929.1

32.8339

35.243.1

49.3°56.7"59.9*

58.0°66.476.7

yly

84%

-3%

7%27%

47%37%*41%*

18%28%*

yly,statedpercompanyWuXiBiologics

13%

30%*

12%in2Q18%in3Q*

17%*36%in3Q*

Totalbacklog,USSbn

11.313.6

20.620.1

20.620.1

18.5°20.3*

23.725.1

yy

20%

51%9%

o%0%

5%*19%*

28%24%*

Totalbacklbogwithin3yrs,USSmn

1,4582.,890

3,6213,503

3,8503,642

3,650°4,210°

4,530°5,500°

yy

98%

25%15%

6%4%

11%*29%*

24%*31%*

WuXiXDC

Servicebacklog,USSmn

318411

579842

9911,329

1,4891,998

yly

82%105%

71%58%

50%50%

Calculatedneworder,USSmn

230

552491

967713

,3131,049

yly,calculated

113%

75%45%

36%47%

yly,statedpercompanyAsymchem

48%

Totalbacklog,USSbn

0.51.9

1.2

0.9

1.11.1

1.41.7

yly

320%

39%

24%

>20%

32%53.8%

Neworder,yly

c.20%

9M25

double

dgit

55%

Tigermed

Backlog,Rmbbn

7.2611.4

13.8

14.1

15.8

18.2

yy

Reportedneworder,Rmbbn

5.5

57%

9.6

21%

9.7

2%

7.9

12%

8.4AugYTD7.0°

15%8.5(9M26)

yly

lo%

19%

7%

midteensgrowth

9M25mid

teensgrowth

30%+25-30%

1.*denotesdataforcontinuingoperationsforWuXiApptecandWuxiBiology;2.Asymchemtotalbacklogdataisasoffinancialreleasedates

Source:Companydata,GoldmanSachsGlobalInvestmentResearch

Exhibit3:Ontrackfor2026guidancedelivery;focusshiftsto2027visibilityatJanuaryindustryconference

AJomalepoa:0rJuSpOcDec

2Apr-JunJuScpOct-Do

rAmalepo0DcThahai

WuXAppTee

一一

FY26revenuegowhof+40-42%ywfocninungcqperaions

WuXuEio

一一一

一▲一FY26reveruegowthguidaned15-18%420-25%atcnstantcurency)

WuXXDC

na.nana.na.

一一

35%gmouprevenuegonthfrFY26onacorestarkourrency.like-fir-Hikeasis(ncuingBnDink)r40%maprofarmabasis

Phamaron

FY2Grerenuegouthat5-20%yincopraingac.3%FXheadand

Aecymchem

一

19-22%yevenuegouthinFY26,neapoainga2-3%FXheadnind

SmsungBioFY2Grenenuegowhof20%+w

Source:Companydata,DatacompiledbyGoldmanSachsGlobalInvestmentResearch

12November20264

GoldmanSachs

tinpasC:/R/OwwC.DMO

12November20265

Exhibit4:Ourestimatesforsalesandnetincome

Sortby2026adj.netincomegrowth

Sales(Rmbmn)

Salesgrowth

Netincome(Rmbmn)

Netincomegrowth

Adj.netincome

(Rmbmn)

Adj.netincomegrowth

Valuation

(PE)

Performance

TickerCompanyname202620272028202620272028202620272028202620272028202620272026202727281M6MCRO/CDMO

1548.HKGenscript9001,2251,559-6%36%27%-10415430981%249%100%-10415481%249%61X31X-20%122%603259.SSWuXiAppTecCo.(A)62,35875,91188,68237%22%17%25,55328,73333,77133%12%18%25,08630,65968%22%14X12X-4%43%2359.HKWuXiAppTecCo.(H)62,35875,91188,68237%22%17%25,55328,73333,77133%12%18%25,08630,65968%22%16X14X-4%48%3347.HKTigermed(H)8,0069,47710,86217%18%15%4601,1191,292-48%143%16%59587968%48%32X24X-13%2%300347.SZTigermed(A)8,0069,47710,86217%18%15%4601,1191,292-48%143%16%59587968%48%50X38X-7%2%2268.HKWuXiXDC8,16111,08614,37237%36%30%1,8092,6613,55822%47%34%2,3512,88936%23%27X21X-11%30%300759.SZPharmaron(A)16,79520,43423,87319%22%17%1,9322,6223,27516%36%25%2,2252,76922%24%29X23X5%69%3759.HKPharmaron(H)16,79520,43423,87319%22%17%1,9322,6223,27516%36%25%2,2252,76922%24%16X13X-2%55%2269.HKWuXiBiologics25,76031,09536,52518%21%17%5,3867,2298,65610%34%20%6,7738,05920%19%22X18X-8%52%6821.HKAsymchem(H)7,9609,92711,77619%25%19%1,2501,7952,13010%44%19%1,5001,91520%28%21X18X-20%23%

002821.SZAsymchem(A)7,9609,92711,77619%25%19%1,2501,7952,13010%44%19%1,5001,91520%28%30X25X-14%25%

Source:GoldmanSachsGlobalInvestmentResearch

Encouragingsignsofearly-stagedemandrecovery

Exhibit5:WXAT’s3Q26newlyadded116preclinical&phase1molecules

250

200

150

100

50

0

NetadditionofPreclinical&Phase1projectsbyquarter

236226

203

181176

116

80

55

4445

22

12

133

167

169

116

128

89

13

111

27

8

Source:Companydata,DatacompiledbyGoldmanSachsGlobalInvestmentResearch

Exhibit7:ChinaCROJoinnLabsalsoachievedrecordhighneworderin3Q26overthepastfewquartersat

Rmb1.4bn...

1.601.401.201.000.800.600.40

0.20

-

0.91

JoinnLabsneworder(4Q24-3Q26,inRmbbn)

1.40

1.11

0.96

0.590.62

0.440.43

4Q241Q252Q253Q254Q251Q262Q263Q26

Source:Companydata,DatacompiledbyGoldmanSachsGlobalInvestmentResearch

Exhibit6:ClinicalCROshowsearlysignofrecoverywithevidentbook-to-billratiohikeYTD

ClinicalCRObook-to-billratio(1Q21-3Q26)

MedpaceIQVIA-R&DsolutionICONCharlesRiver

1.71.61.51.41.3

1.21.1

0.9

1.0

1Q21

2Q21

3Q21

4Q21

1Q22

2Q22

3Q22

4Q22

1Q23

2Q23

3Q23

4Q23

1Q24

2Q24

3Q24

4Q24

1Q25

2Q25

3Q25

4Q25

1Q26

2Q26

3Q26

0.8

Source:Companydata,DatacompiledbyGoldmanSachsGlobalInvestmentResearch

Exhibit8:...withbook-to-billratioreachedabove2.8xthrough1Q-3Q26

JoinnLabsbook-to-billratio(4Q24-3Q26)

3.503.002.502.001.501.00

0.50

-

4Q241Q252Q253Q254Q251Q262Q263Q26

Source:Companydata

12November20266

Exhibit9:AIDDExposure:Genscriptremainasakeybeneficaryfromgenesynthesis,followedbyPharmaron/WuXiBioonlabanalysisandproteinsynthesis

Company

Company'scommentsonAIDDandGSe

GenScript

-ManagementexpectstheAIDDaddressablemarkettogrowata50-80%CAGRover2026-29fromc.US$1bnin2026andtargetsGenScripttooutgrowthemarketthroughsharegains.AI-relatedrevenueisalreadyc.20%of

thegene-to-proteinplatformandrising.

-ManagementplanstoatleastdoubleAIDDcapacityeverysixmonths,supportedbyincreasinglyrecurringclientdemand.Repeat-ordercycleshaveshortenedto10-12days,orderfrequencyhasincreased2.5x,and70%of

backlogcomesfromclientsundermasterserviceagreements,strengtheningconfidenceindemandsustainability

-GSe:WeforecastAIDDrevenueofUS$170mninFY26andUS$399mninFY27,implying+135%y/ygrowthinFY27.

Pharmaron

-AIDD-relatedprojectsarec.8%ofLaboratoryServicesrevenue

-AI-focusedbiotechswere2ofthetop-20and4ofthetop-50clientsin2025.ExposuretoAIDDbiotechsdatesbackto2018

WuXiBiologics

SupportedbyAIDD-relateddemand,protein-relatedbusinessgrew40%+y/yin1H26;totalprotein-relatedrevenueisexpectedtoapproachUS$200mninFY26

Source:Companydata,GoldmanSachsGlobalInvestmentResearch

12November20267

Funding:monitoringtheIPOfundinginnextfewmonthsfollowingSepFedHike

Exhibit10:GlobalHCfundingturningflattishafterrecovery...

EquityfundingforUShealthcare(IPOs/FOs)bymonth

US$bnEquityfundingforUShealthcare(IPOs/FOs)-12mrolling

USIPO&FOfundingamount12mrollingaverageaverage

average

14

12

10

8

6

4

2

-

Apr-21

Jun-21

Aug-21

Oct-21

Dec-21

Feb-22

Apr-22

Jun-22

Aug-22

Oct-22

Dec-22

Feb-23

Apr-23

Jun-23

Aug-23

Oct-23

Dec-23

Feb-24

Apr-24

Jun-24

Aug-24

Oct-24

Dec-24

Feb-25

Apr-25

Jun-25

Aug-25

Oct-25

Dec-25

Feb-26

Apr-26

Jun-26

Aug-26

Oct-26

Source:Wind

Exhibit12:ChinapublicHCfundingremainedlightinOct...

EquityfundingforChinahealthcare(IPOs/FOs)bymonth

US$bn

EquityfundingforChinahealthcare(IPOs/FOs)-12mrollingaverage

10

9

8

7

6

5

AshareHshareADR12mrollingaverageaverage

4

3

2

1

-

Apr-21

Jun-21

Aug-21

Oct-21

Dec-21

Feb-22

Apr-22

Jun-22

Aug-22

Oct-22

Dec-22

Feb-23

Apr-23

Jun-23

Aug-23

Oct-23

Dec-23

Feb-24

Apr-24

Jun-24

Aug-24

Oct-24

Dec-24

Feb-25

Apr-25

Jun-25

Aug-25

Oct-25

Dec-25

Feb-26

Apr-26

Jun-26

Aug-26

Oct-26

Source:Wind

Exhibit14:EquityfundingforUShealthcarereachedUS$43bnYTD,highestsince2021

AsofOct2026

US$bnEquityfundingforUShealthcare(IPOs/FOs)

70.0060.0050.0040.0030.0020.00

10.00

-

Equityfundingamount

60.63

56.00

112%

46.21

62%

33.66

37%

20.80-14%

-49%

-66%

yoy

98%

42.4242.88

37%

39.03

30.89

21.61

-16%

14.54

-74%

20212022202320242025YTD21YTD22YTD23YTD24YTD25YTD26

150%

100%

50%

0%

-50%

-100%

Source:Wind

Exhibit11:...asglobalprivatebiotechfundingstaysintact

Globalprivatebiotechfundingbymonth

Apr-21

Jul-21

Oct-21

Jan-22

Apr-22

Jul-22

Oct-22

Jan-23

Apr-23

Jul-23

Oct-23

Jan-24

Apr-24

Jul-24

Oct-24

Jan-25

Apr-25

Jul-25

Oct-25

Jan-26

Apr-26

Jul-26

Oct-26

US$,mnGlobal(excl.China)BiotechPrivateFunding

PrimaryfundingamountRollingaverage

AverageInvestmentevent

7000

6000

5000

4000

3000

2000

1000

0

100

90

80

70

60

50

40

30

20

10

0

Source:Pharmcube

Exhibit13:...versussustainedamountforChinaprivatebiotechfunding

Chinaprivatebiotechfundingbymonth

Apr-21

Jul-21

Oct-21

Jan-22

Apr-22

Jul-22

Oct-22

Jan-23

Apr-23

Jul-23

Oct-23

Jan-24

Apr-24

Jul-24

Oct-24

Jan-25

Apr-25

Jul-25

Oct-25

Jan-26

Apr-26

Jul-26

Oct-26

US$,mnChinaBiotechPrivateFunding

2500

PrimaryfundingamountRollingaverage

AverageInvestmentevent

2000

1500

1000

500

0

100

90

80

70

60

50

40

30

20

10

0

Source:Pharmcube

Exhibit15:...whileChinawasrelativelysoftduetotheregulatorychangeforH-sharelistings

AsofOct2026

US$bnEquityfundingforChinahealthcare(IPOs/FOs)

45.0040.0035.0030.0025.0020.0015.00

10.005.00

-

-60%

-60%

39.24

314%

280%

21.13

16.89

8.37

4.44

-46%-47%

29.67

18.07

14.49

7.257.73

3.50

-52%

-9%

-39%

-47%

Equityfundingamountyoy

20212022202320242025YTDYTDYTDYTDYTDYTD212223242526

350%

300%

250%

200%

150%

100%

50%

0%

-50%

-100%

Source:Wind

12November20268

Exhibit16:GlobalM&AactivityYTDreachedafive-yearhigh...

NumberandtotalvalueofM&Adealsannouncedeachyear,asofOct2026

US$bn

GlobalM&A

TotalvalueM&Adeals

180

160

140

120

100

80

60

40

20

0

148.96

115

73

75.36

54.42

54

154.25

130.32

54.38

86

98

59

20212022202320242025

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论